All things are active … new approach methods for excipient safety.

Excipients make up the majority of most medicines by mass, yet they are still called "inactive," still largely qualified against a 2005 guidance, and still assessed product by product with animal studies that answer the wrong questions. The past decade has dismantled the "inactive" assumption: polyethylene glycol and polysorbate anaphylaxis, benzyl alcohol gasping syndrome, propylene glycol acidosis, benzalkonium bronchospasm, and the recurrent diethylene glycol mass poisonings of children all show that excipient risk is real, but that it is contextual rather than intrinsic. I argue that this contextual character makes excipients an almost ideal proving ground for New Approach Methodologies (NAMs). Excipient hazard depends on route, dose, duration, formulation, impurities, and patient population-exactly the variables that exposure science, computational toxicology, and human in vitro systems handle well and that whole-animal testing handles poorly. I propose replacing the test-list mentality with a context-of-use excipient safety passport, sketch where NAMs already carry decisions and where they only inform them and offer a phased implementation agenda. The goal is to convert excipient safety from a static checklist into a human-relevant, exposure-led, mechanistic discipline.